|
Mar 4
|
Daiichi Sankyo and AstraZeneca’s Enhertu shows OS improvements in Phase III trial
|
|
Mar 3
|
ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Overall Survival in Patients with HER2 Positive Metastatic Gastric Cancer at Interim Analysis of DESTINY-Gastric04 Phase 3 Trial
|
|
Feb 28
|
ENHERTU® Recommended for Approval in the EU by CHMP for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following at Least One Endocrine Therapy
|